Actinium Pharmaceuticals highlights Iomab-ACT clinical results in CAR T-cell therapy at ASH 2026
ATNM•ATNM•ATNM•ATNM•Actinium Pharmaceuticals released three Iomab-ACT clinical abstracts for presentation at the 2026 American Society of Hematology meeting, including findings on conditioning before CAR T-cell therapy and preliminary sickle cell disease research.
Actinium Pharmaceuticals released three Iomab-ACT clinical abstracts for presentation at the 2026 American Society of Hematology meeting. Memorial Sloan Kettering findings suggest potential for immune-cell depletion before investigational CAR T-cell therapy while preventing severe inflammatory and neurological toxicities. A Phase 1b/2 trial evaluates Iomab-ACT conditioning before commercial CD19-directed CAR T-cell therapy; preliminary severe sickle cell disease findings explore chemotherapy-free conditioning for donor engraftment, with presentation scheduled for December 13, 2026.
